Zydus receives USFDA approval for Cevimeline Hydrochloride Capsules 30mg

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Cevimeline Hydrochloride Capsules 30 mg, (USRLD: Evoxac Capsules, 30 mg).

Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sjren's syndrome. Cevimeline is a muscarinic receptor agonist that stimulates salivary secretion.

Cevimeline hydrochloride 30 mg capsules will be produced at the Group's manufacturing facility at SEZ-II, Ahmedabad.

Cevimeline Hydrochloride Capsules 30mg had annual sales of USD 26.9 mn. (IQVIA MAT Jan-26).

Powered by Capital Market - Live News